Is GLP-1 the Same as Tirzepatide? What the Evidence Actually Shows

Why GLP-1 receptor agonists were just the beginning

GLP-1 (glucagon-like peptide-1) is a hormone released by the gut after eating. It signals to the brain that you are full, slows gastric emptying, and helps regulate blood sugar. Medicines that mimic this signal, called GLP-1 receptor agonists, have been used in diabetes care for years and more recently licensed for weight management. Semaglutide (sold as Wegovy for weight loss) is the most established example in the UK.

Researchers noticed, however, that GLP-1 is not the only gut hormone with these properties. GIP (glucose-dependent insulinotropic polypeptide) also plays a role in energy balance and appetite, working through a distinct receptor. The question became whether activating both receptors together would produce a stronger or more sustained effect than either alone. Tirzepatide was designed to answer that question. It is a single molecule that binds to both the GLP-1 and GIP receptors, which is why calling it simply a GLP-1 medicine is technically incomplete. You can read more about the mechanism on the tirzepatide overview page.

The NHS describes tirzepatide as a dual GIP and GLP-1 receptor agonist, and this classification appears on official UK sources including the NHS tirzepatide medicines page. That framing is the right one to use when comparing it with other medicines in the same broad class.

What the trial data shows when both receptors are activated

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no diabetes to tirzepatide or placebo over 72 weeks. At the highest dose tested, participants lost around 20–21% of their body weight on average, a figure that, at the time, exceeded the results seen in equivalent trials of any single-pathway GLP-1 medicine. NICE cited this evidence in its December 2024 appraisal of tirzepatide (TA1026), recommending it for eligible adults within the NHS.

The more direct comparison came from SURMOUNT-5, a head-to-head trial published in 2025 in the New England Journal of Medicine. Over 72 weeks, adults with obesity and no diabetes lost significantly more weight on tirzepatide than on semaglutide 2.4mg. That finding confirmed what the separate SURMOUNT and STEP trial programmes had individually suggested: that dual receptor activation produces a larger average reduction than single GLP-1 pathway activation at the doses currently licensed.

It is worth being precise about what this means in practice. Trial averages mask a wide range of individual responses. Some people do exceptionally well on a single-pathway GLP-1 medicine; others may respond more strongly to the dual mechanism. Which is more appropriate for you depends on your health history, existing conditions, and how you tolerate each medicine, a judgement that belongs in a clinical conversation, not a comparison table.

Questions about how Mounjaro sits within this evidence base come up often. The page on GLP-1 and Mounjaro covers that angle specifically if you want to explore it further.

So is tirzepatide a GLP-1 medicine or not?

The short answer: it contains GLP-1 receptor activity, so it is sometimes grouped under the GLP-1 umbrella in everyday conversation and press coverage. That is understandable shorthand. Strictly, though, it belongs to its own category: dual GIP and GLP-1 receptor agonist. In UK licensing, in the Mounjaro SmPC, and in NHS communications, this distinction is consistently made.

Practically, this matters because the two receptor systems interact differently with other medicines and physiology. The guidance on whether tirzepatide and Mounjaro are the same thing explains the brand-versus-molecule question, which often comes up alongside this one. If you have also come across references to tirzepatide peptide and wondered whether tirzepatide peptide is the same as Mounjaro, that page works through the distinction clearly. And if you have seen the name Manjaro used online, that is a common misspelling, there is no licensed medicine by that name, as the Manjaro and tirzepatide page sets out.

For cost context, the UK price landscape for Mounjaro changed substantially from September 2025 onwards. The Eli Lilly price increase page covers what happened and what private patients typically pay now.

Getting access to tirzepatide in the UK

Tirzepatide is available in the UK as Mounjaro, manufactured by Eli Lilly. It comes as a once-weekly subcutaneous injection via a pre-filled KwikPen, with strengths from 2.5mg up to 15mg. Treatment begins at 2.5mg (that starting dose exists to let your body adjust, not as a therapeutic target) and is titrated by the prescriber, typically in four-week steps. The pen that arrives is tracked by DPD, dispatched the same day your prescription is issued, in plain packaging with nothing on the outside to indicate what is inside.

Because tirzepatide is a prescription-only medicine, a prescriber must review your full health picture before it can be issued. At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber, a real clinician, not software. Eligibility broadly follows the licensed criteria: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. BMI alone is never the whole picture; the prescriber considers your full history. For a fuller look at the treatment options, the weight-loss treatments overview is a good starting point.

If you are ready to find out whether tirzepatide is clinically suitable for you, you can start your free consultation with our prescribers today.